ArticleJournal of translational medicine2026
Midkine as a novel prognostic and therapeutic target in meningioma: insights from single-cell analysis and organoid-based drug validation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tumor location and morphological MRI features in relation to combined 1p/22q deletion in meningioma.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRecurrent meningiomas lack effective treatments beyond surgery and radiotherapy, necessitating novel prognostic biomarkers and therapeutic targets.
methodsSingle-cell RNA sequencing coupled with the Scissor algorithm, along with bulk transcriptomic analysis, was used to identify recurrence-associated genes in meningiomas. Clinical prognostic value was assessed using WB, ELISA, and IHC. Functional validation involved MDK knockdown and pharmacological inhibition with iMDK in IOMM-Lee and CH157 meningioma cells. Multiplex immunofluorescence staining was used to verify immune cell infiltration. Meningioma organoids were generated to evaluate the efficacy of iMDK.
resultsMDK, a key gene of recurrence-associated subclusters, is significantly overexpressed in recurrent meningiomas. Plasma MDK levels are markedly elevated in patients with recurrence propensity. IHC confirmed higher MDK expression in recurrent cases, which, after adjusting for confounding factors, correlates with shorter progression-free survival. Knockdown and iMDK administration reduced proliferation and clonogenicity in IOMM-Lee and CH157 meningioma cells. Additionally, high-MDK meningiomas exhibited immunosuppressive features, including reduced CD8+/CD4+ T-cell infiltration. Furthermore, iMDK induced structural disintegration of meningioma organoids and cell death.
conclusionsMDK is a key recurrence marker and participates in meningioma progression, promoting proliferation and immunosuppression. Targeting MDK effectively inhibits tumor growth and induces organoid disintegration, highlighting its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.